glp-1 binge eating disorder GLP-1s may reduce and similar behaviours in people living with obesity, suggests the most comprehensive systematic review and meta-analysis to date, published in eClinicalMedicine. Find out more 👉 http://spkl.io/61897yUsZ Figure GLP-1 for Severe Obesity, PCOS

Tirzepatide FDA-approved as Mounjaro for type 2 diabetes (2022) and Zepbound for obesity (2023)

References An W, Dong X, Tan B, Yang Q, Chi S, Zhang S, Liu H, Yang Y (2021) Dietary n-3 long chain polyunsaturated fatty acids affect the serum biochemical parameters, lipid-metabolism-related of gene expression and intestinal health of juvenile hybrid grouper ( Epinephelus fuscoguttatus Epinephelus lanceolatu)

Type 2 diabetes and broader cardiometabolic groups remain important where GLP-1 medicines support glucose control and risk reduction

If your clinician flags kidney function issues, expect annual or twice-yearly creatinine monitoring per FLOW (Perkovic et al

(2005) 289:H24018